GlaxoSmithKline (LON:GSK) has been assigned a GBX 2,110 ($27.57) price objective by investment analysts at HSBC in a report issued on Tuesday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. HSBC’s price target would indicate a potential upside of 28.22% from the stock’s previous close.
A number of other equities analysts also recently weighed in on GSK. Citigroup reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, September 3rd. Shore Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline in a research note on Thursday, August 22nd. Goldman Sachs Group set a GBX 1,900 ($24.83) price target on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Friday, August 23rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research note on Thursday, August 29th. Finally, Kepler Capital Markets set a GBX 1,600 ($20.91) price target on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Tuesday, August 27th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of GBX 1,682.86 ($21.99).
LON GSK opened at GBX 1,645.60 ($21.50) on Tuesday. GlaxoSmithKline has a 1-year low of GBX 1,408.80 ($18.41) and a 1-year high of GBX 1,767 ($23.09). The company has a current ratio of 0.71, a quick ratio of 0.44 and a debt-to-equity ratio of 1,127.74. The company has a market capitalization of $82.69 billion and a PE ratio of 18.53. The firm’s fifty day simple moving average is GBX 1,681.02 and its 200-day simple moving average is GBX 1,591.26.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Read More: Are sell-side analysts objective?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.